comparemela.com

Latest Breaking News On - Lars fruergaard - Page 5 : comparemela.com

Wegovy sales double as weight loss drug boom powers Novo Nordisk

Sales of the Danish pharma giant's obesity drugs grew 25% year over year in this year's first quarter

United statesLars fruergaardNovo nordiskDoug langDanish kroneNorth americaAnti obesity medicationLars fruergaard jørgensenPeptide therapeuticsDoug langOvo holdingsa sLars fruergaardPeptide hormones

Novo Nordisk beats profit estimates as sales of weight loss drug Wegovy more than double

Sales of popular weight loss drug Wegovy more than doubled to 9.38 billion kroner.

United statesNovo nordiskJohn rountreeEli lillyLars fruergaardEuropean unionNorth americaBox europe

Novo Nordisk s sales increased by 22% in Danish kroner and by 24% at constant exchange rates to DKK 65 3 billion in the first three months of 2024

Bagsværd, Denmark, 2 May 2024 - financial report for the period 1 January 2024 to 31 March 2024 Operating profit increased by 27% in Danish kroner and by 30% at constant exchange rates to DKK.

United statesLars fruergaardNovo nordiskFrederik taylor pitterDaniel muusmann bohsenAmbre james brownDavid heiberg landstedSina meyerJacob martin wiborgYork stock exchangeCatalent incSales in international operationsNovo holdingsNorth america operationsInternational operationsNasdaq copenhagen

Novo Nordisk s Earnings Beat Estimates on Surging Demand for Its Weight-Loss Drugs

Danish drugmaker Novo Nordisk saw revenue and profits jump year-over-year as demand for its weight loss drugs Ozempic and Wegovy surged.

United statesLars fruergaardNovo nordiskWegovy demand drives salesNorth americanEli lilly

Big Pharma Q1 earnings roundup: Novo, Moderna and Regeneron report

Novo continues to soar on GLP-1 sales, while Moderna and Regeneron look to pick up the pace.

United statesLars fruergaardEli lillyLeonards schleiferAgios pharmaceuticalsBlackstone life sciencesBausch healthNovo holdingsCardior pharmaceuticalsNovo nordiskAlnylam pharmaceuticalsNorth americaSan diego basedBlueprint medicinesArbutus biopharma

vimarsana © 2020. All Rights Reserved.